<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> protein, FANCJ, directly interacts with MLH1, a key protein involved in DNA mismatch repair </plain></SENT>
<SENT sid="1" pm="."><plain>Deficient mismatch repair, or microsatellite instability, is a potent marker for the ineffectiveness of <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the significance of FANCJ expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, focusing on the effects of 5-FU-based adjuvant chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Clinicopathologic features and immunohistochemical expression of FANCJ and MLH1 were studied in 219 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We also analyzed 5-FU sensitivity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines with varying levels of FANCJ expression </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: FANCJ expression was elevated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues compared with <z:mpath ids='MPATH_458'>normal</z:mpath> epithelial tissue </plain></SENT>
<SENT sid="6" pm="."><plain>High expression of FANCJ was significantly associated with 5-FU resistance measured by the SDI test (P &lt; 0.05) and poor recurrence-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients with stage II/III <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> who received 5-FU, patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> exhibiting high FANCJ expression had significantly worse <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> than did patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> exhibiting low FANCJ expression (P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Among patients who did not receive adjuvant chemotherapy, FANCJ expression was not correlated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> (P = 0.76) </plain></SENT>
<SENT sid="9" pm="."><plain>High FANCJ expression was correlated with 5-FU resistance in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with <z:mpath ids='MPATH_458'>normal</z:mpath> MLH1 expression (P &lt; 0.05) but not in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> not expressing MLH1 (P = 0.9) </plain></SENT>
<SENT sid="10" pm="."><plain>In vitro, FANCJ overexpression was correlated with 5-FU resistance in MLH1-proficient HCT116 3-6 cells but not in MLH1-deficient HCT116 cells </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: FANCJ could be a useful biomarker to predict the response to 5-FU and prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, particularly in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with <z:mpath ids='MPATH_458'>normal</z:mpath> MLH1 expression </plain></SENT>
</text></document>